Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen has renegotiated its 2010 partnership agreement with Inspiration Biopharmaceuticals to develop and commercialize Inspiration recombinant products OBI-1and IB1001, used to treat hemophilia A and hemophilia B.
Subscribe to our email newsletter
As part of the new agreement, Ipsen will gain commercial rights in key territories, while Inspiration will develop OBI-1 and IB1001 across the world.
Under the negotiation, Ipsen will receive $30m upfront payment and Ipsen is also entitled to pay Inspiration milestones for a total amount of up to $200m, of which $27.5m are regulatory milestones and the remaining are commercial milestones.
As part of the new agreement, Ipsen will also appoint two additional members to Inspiration’s board of directors and will receive a mid-twenties royalty on sales of OBI-1.
The agreement also states that Ipsen will invest up to $20m in Inspiration.